CAI
Caris Life Sciences, Inc.
32.00$
-0.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 21 | Q3 21 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +13.1% | -175.7% | – | – | – | – | – | +756.5% | -28.3% | -26.6% | +86.6% | – | |
| – | +11.6% | -46.2% | -34.4% | +6.4% | -11.2% | -35.8% | -9.0% | -24.0% | -11.9% | +18.0% | +129.1% | – | |
| – | -4.6% | +687.6% | +0.6% | +5.3% | +5.4% | +195.2% | +92.6% | -51.7% | -2.1% | +18.7% | +140.0% | – | |
| – | -22.8% | -105.5% | – | – | – | – | -110.8% | – | -519.5% | – | -318.2% | – | |
| – | +418.8% | -99.7% | +48.9% | -29.4% | +25.3% | +17.4% | -48.5% | +411.9% | -28.3% | +103.2% | +213.5% | – | |
| – | +517.5% | – | -104.3% | -29.4% | +25.3% | +17.4% | -48.5% | +411.9% | -28.3% | +103.2% | +1,181.5% | – | |
| – | +0.1% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -75,372.7% | -99.5% | -100.0% | – | – | |
| – | – | – | -100.0% | – | – | – | – | -100.1% | – | -101.0% | +32,022.5% | – | |
| – | – | -53.3% | -100.1% | – | +159.8% | +468.6% | +52,927.4% | -103.1% | – | -75.8% | -4,478.5% | – | |
| – | – | +1,576.6% | -135.3% | – | – | – | – | -95.0% | +25.6% | -45.8% | -559.6% | – | |
| – | – | – | – | – | – | – | – | +837.5% | -28.3% | -43.2% | +28.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.